Menu Search
Equities

Royalty Pharma PLC

RPRX:NSQ

Royalty Pharma PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)28.20
  • Today's Change-0.015 / -0.05%
  • Shares traded570.19k
  • 1 Year change+2.83%
  • Beta0.4633
Data delayed at least 15 minutes, as of Sep 19 2024 17:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy2
Outperform4
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for Royalty Pharma plc have a median target of 46.00, with a high estimate of 60.00 and a low estimate of 28.00. The median estimate represents a 63.06% increase from the last price of 28.21.
High112.7%60.00
Med63.1%46.00
Low-0.7%28.00

Dividends in USD

In 2023, Royalty Pharma PLC reported a dividend of 0.80 USD, which represents a 5.26% increase over last year. The 4 analysts covering the company expect dividends of 0.92 USD for the upcoming fiscal year, an increase of 14.88%.
Div growth (TTM)5.26%
More ▼

Earnings history & estimates in USD

On Aug 08, 2024, Royalty Pharma plc reported 2nd quarter 2024 earnings of 0.96 per share. This result was in line with the consensus of the 6 analysts following the company and exceeded last year's 2nd quarter results by 14.29%.
The next earnings announcement is expected on Nov 06, 2024.
Average growth rate+5.70%
Royalty Pharma plc reported annual 2023 earnings of 4.50 per share on Feb 15, 2024.
Average growth rate+22.67%
More ▼

Revenue history & estimates in USD

Royalty Pharma plc had 2nd quarter 2024 revenues of 608.00m. This missed the 628.53m consensus estimate of the 4 analysts following the company. This was 11.11% below the prior year's 2nd quarter results.
Average growth rate+3.98%
Royalty Pharma plc had revenues for the full year 2023 of 2.36bn. This was 5.27% above the prior year's results.
Average growth rate+3.62%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.